Overall NAGE gets a fundamental rating of 7 out of 10. We evaluated NAGE against 58 industry peers in the Life Sciences Tools & Services industry. While NAGE has a great health rating, its profitability is only average at the moment. An interesting combination arises when we look at growth and value: NAGE is growing strongly while it also seems undervalued. With these ratings, NAGE could be worth investigating further for value and growth investing!.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year NAGE was profitable.
In the past year NAGE had a positive cash flow from operations.
In the past 5 years NAGE reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NAGE reported negative operating cash flow in multiple years.

1.2 Ratios

NAGE has a Return On Assets of 20.82%. This is amongst the best in the industry. NAGE outperforms 96.49% of its industry peers.
The Return On Equity of NAGE (28.91%) is better than 94.74% of its industry peers.
The Return On Invested Capital of NAGE (20.22%) is better than 94.74% of its industry peers.

		Industry Rank	Sector Rank
ROA	20.82%
ROE	28.91%
ROIC	20.22%

ROA(3y)-9.02%

ROA(5y)-25.18%

ROE(3y)-18.83%

ROE(5y)-52.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NAGE has a Profit Margin of 16.38%. This is amongst the best in the industry. NAGE outperforms 87.72% of its industry peers.
With a decent Operating Margin value of 15.48%, NAGE is doing good in the industry, outperforming 78.95% of the companies in the same industry.
Looking at the Gross Margin, with a value of 63.89%, NAGE belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
In the last couple of years the Gross Margin of NAGE has grown nicely.

		Industry Rank	Sector Rank
OM	15.48%
PM (TTM)	16.38%
GM	63.89%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.17%

GM growth 5Y2.12%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NAGE has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
NAGE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NAGE has been increased compared to 5 years ago.
The debt/assets ratio for NAGE has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 10.86 indicates that NAGE is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 10.86, NAGE belongs to the best of the industry, outperforming 94.74% of the companies in the same industry.
NAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	10.86

ROIC/WACC1.82

WACC11.1%

2.3 Liquidity

NAGE has a Current Ratio of 4.12. This indicates that NAGE is financially healthy and has no problem in meeting its short term obligations.
NAGE's Current ratio of 4.12 is fine compared to the rest of the industry. NAGE outperforms 61.40% of its industry peers.
A Quick Ratio of 3.29 indicates that NAGE has no problem at all paying its short term obligations.
NAGE's Quick ratio of 3.29 is fine compared to the rest of the industry. NAGE outperforms 64.91% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.12
Quick Ratio	3.29

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 2300.00% over the past year.
NAGE shows a strong growth in Revenue. In the last year, the Revenue has grown by 36.04%.
The Revenue has been growing by 16.56% on average over the past years. This is quite good.

EPS 1Y (TTM)2300%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%150%

Revenue 1Y (TTM)36.04%

Revenue growth 3Y13.87%

Revenue growth 5Y16.56%

Sales Q2Q%32.86%

3.2 Future

NAGE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.22% yearly.
Based on estimates for the next years, NAGE will show a very strong growth in Revenue. The Revenue will grow by 22.85% on average per year.

EPS Next Y85.64%

EPS Next 2Y73.46%

EPS Next 3Y64.95%

EPS Next 5Y59.22%

Revenue Next Year30.96%

Revenue Next 2Y25.55%

Revenue Next 3Y23.66%

Revenue Next 5Y22.85%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 25.04, NAGE can be considered very expensive at the moment.
Based on the Price/Earnings ratio, NAGE is valued cheaper than 80.70% of the companies in the same industry.
NAGE's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.21.
NAGE is valuated rather expensively with a Price/Forward Earnings ratio of 19.97.
91.23% of the companies in the same industry are more expensive than NAGE, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 25.98, NAGE is valued a bit cheaper.

		Industry Rank	Sector Rank
PE	25.04
Fwd PE	19.97

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NAGE indicates a somewhat cheap valuation: NAGE is cheaper than 75.44% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, NAGE is valued cheaply inside the industry as 87.72% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	22.68
EV/EBITDA	20.69

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of NAGE may justify a higher PE ratio.
NAGE's earnings are expected to grow with 64.95% in the coming years. This may justify a more expensive valuation.